During the 50st Congress of the International Society of Pediatric Oncology (SIOP) in November 2018, in Kyoto, Japan, Dr Christophe Grosset, who heads the MiRCaDe team, received a poster award at the “Solid and CNS Tumours: Clinical” Session.
At this occasion, Dr Christophe Grosset presented his last results about the transcriptional study of 25 hepatoblastoma samples by RNA-seq. This work, published in Hepatology journal (https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.29672) led to the design of a new 4-gene signature that can be used by pathologists for the stratification of tumors, the identification of a new oncogenic pathway (e.g. Fanoni Anemia pathway) and a novel treatment option using Velcade for patients with a C2A-type proliferative hepatoblastoma.
Our team uses different in vitro and in vivo experimental approaches to study biological phenomena driving tumorigenesis. Its projects focus on the role of signaling pathways, genes and microRNAs in different types of adult and pediatric cancers with bad prognosis. The team has validated its competences by patenting novel therapeutic molecules and establishing novel tumor models in mice and chick embryo for drug screening.
The MiRCaDe team is not located in the same building than the unit. Follow this map :